the obstructed airway and sympathetic nervous system overactivity. [5, 6] Repetitive apnea-hypopnea produces intermittent hypoxia and re-oxygenation, which promotes oxidative stress in the presence of increased production of reactive oxygen species (ROS). The latter promotes systemic inflammation and atherosclerosis, which may have significant adverse cardiovascular effects. [7, 8] The patient complains of loud snoring, stoppage of breathing, daytime somnolence, and excessive chronic fatigue. As the disease progresses the patient may develop a range of morbidities. The latter manifests as daytime hypoxemia, systemic hypertension, [9] myocardial ischemia, [10, 11] stroke, [12] diabetes, metabolic syndrome, [13] increased cardiovascular morbidity, and mortality, [14] and higher risk of automobile and workplace accidents. [15] Obstructive sleep apnea-hypopnea syndrome patients often suffer from pulmonary disability due to poor exercise capacity of multifactorial origin. These include cardiovascular abnormalities including pulmonary hypertension and cardiac failure; nocturnal/daytime hypoxemia and tissue hypoxia; fragmented sleep; excessive daytime sleepiness (EDS) causing muscle fatigue; obesity requiring high energy cost of breathing and a sensation of dyspnea; smoking-related COPD overlap; diabetic myopathy, and de-conditioning of the musculoskeletal system.
Treatment with nasal continuous positive airway pressure (n-CPAP) and BIPAP is known to be effective in treating OSAHS. It relieves sleep-related symptoms, improves cardiopulmonary indices and exercise endurance, and is also reported to reduce mortality. [16, 17] Most workers acknowledge that four or more hours of CPAP use per night significantly improves the symptoms. [18] Data on the exercise characteristics of OSAHS patients is fairly limited in the published literature. Assessment of the cardiopulmonary responses to exercise may be relevant to predicting mortality from cardiovascular disease and understanding the physiological adaptation that occurs in response to hypoxia-re-oxygenation injury during sleep apnea. [19] To the best of our knowledge, a study on cardiopulmonary responses to exercise in OSAHS has not been reported from India.
The present study was undertaken in a group of patients diagnosed with moderate-to-severe OSAHS, to evaluate short-term nocturnal nCPAP therapy for clinical effects and cardiopulmonary responses to exercise.
MATERIALS AND METHODS
An outpatient-based prospective study in patients diagnosed with moderate and severe OSAHS was conducted between April 2010 and January 2012, in the Department of Respiratory, Sleep, Allergy, and Critical Care Medicine of the Metro Group of Hospitals, NOIDA. The study was approved by the Institutional Ethics Committee. The purpose and protocol of the study were discussed with each patient and his/her consent was also obtained in writing.
Patient selection and study protocol
During the period of study, a total of 96 adult patients, referred to our Sleep Laboratory for symptoms of loud snoring, daytime somnolence, and fatigue were clinically evaluated for OSAHS. Patients with thyroid disease, abnormal chest radiograph or with clinical evidence of neurological, hepatic, renal or peripheral vascular disease were excluded. Those with a history of alcohol or substance abuse, current smokers, and those already on CPAP treatment were also excluded.
Patients with an Epworth sleepiness score (ESS) of ≥10 [20] were subjected to attend overnight polysomnography (PSG). Twenty consecutive patients, who met the criteria of moderate to severe OSAHS with an apnea-hypopnea index (AHI) of ≥15 per hour, were inducted into the present study. A verbal assurance of full cooperation for at least five weeks or till conclusion of the study was obtained from each of the twenty patients. All patients were advised nCPAP therapy for eight hours daily, without interruption, for four weeks. Fifteen patients who readily agreed to undergo nCPAP therapy constituted the 'study group'. Five patients, who declined nCPAP therapy, but agreed to remain under observation for the next five weeks, were assigned to the 'control group'.
Investigations

Overnight polysomnography
The patient slept overnight in the Sleep Laboratory to get familiarized with the environment of the actual sleep study to be performed the next night. Attended-PSG was performed with a 32-channel polysomnograph (Medcare Embla S7000 with Video) and the sleep data were scored as per international standards. [21, 22] The video attachment helped in visualizing the patients at arousal. Electrodes for electroencephalogram (EEG-C4/A1, C3/A2), electro-oculogram (EOG), and sub-mental electromyography (EMG) were placed as per the international 10-20 system for sleep staging. Respiratory movements and nasal/oral airflow were recorded by inductance plethysmography and a thermocouple, respectively. Arterial oxygen saturation and pulse rate were also continuously recorded. The bilateral tibial EMG and electrocardiogram (EKG) were monitored from surface electrodes. The following measurements were made or derived from the overnight sleep data as per international practice. [22] • Overnight fixed nasal continuous positive airway pressure titration All study group patients underwent manual CPAP titration in the laboratory, using the Resmed machine and a comfortably fitting nasal mask, ensuring ≥90% arterial oxygen saturation, minimal leak, and AHI below five per hour. The median, highest, and optimal pressures were recorded.
Spirometry
A baseline spirometry test was performed on all patients with Quark PFT-4, as per the American Thoracic Society (ATS) guidelines. [23] The flow-volume loops were analyzed for FVC and FEV 1 -before and after inhalation of 500 µg salbutamol aerosol.
Cardiac evaluation
A 12-lead EKG and 2-D echocardiography were performed on each patient. The echocardiograph was analyzed for wall-motion abnormality, left ventricular ejection fraction, systolic pulmonary hypertension, intracardiac shunts, and left ventricular (LV) systolic and diastolic dysfunction. Cardiac failure was diagnosed as per the European Society of Cardiologists criteria. [24] Cadiopulmonary exercise test Symptom-limited incremental CPET was performed according to the American Thoracic Society protocol, [25] on an elecronically braked bicycle ergometer (ERGOSELECT 200P/200K), with the seat adjusted, to avoid maximal extension of the knee joint during biking. The various exercise parameters (see RESULTS) were either measured directly or derived from the raw data.
The six-minute walk test was performed as per the ATS guidelines. [26] Nocturnal continuous positive airway pressure therapy All study group patients were administered nocturnal nCPAP therapy for at least eight hours each night for an uninterrupted period of four weeks. Treatment for concomitant health problems, if any, was continued as before without altering the dosing or frequency. Each patient was supplied with an nCPAP machine for home use after fully training him/her in its use, routine care, and maintenance. If faced with any technical problem the patient would contact the hospital maintenance staff for prompt redressal or rectification. Compliance to CPAP use was checked on the downloaded data from the machine. Patients in the control group, who were not treated with nCPAP, were simply kept under 'routine observation' for four weeks. At the end of four weeks all patients were again evaluated clinically and assessed with spirometry, 6MWT, ECG, echocardiography, and CPET.
Statistical analysis of data
Clinical and other investigational data were analyzed using SPSS 16, mainly to find the level of significance and the difference in various parameters before and after intervention in the study group and the initial and after four-week 'just-observation' in the control group patients. Similarly, between-group comparisons were also made.
RESULTS
The results of comparative statistical analysis of clinical, sleep, 6MWT, and CPET data between the study group and control group patients are presented below.
Anthropometric, clinical, spirometry, and sleep data
The findings of between-group analysis of demographic data -study group versus control group were: Gender -M/F (11/4 vs. 5/0); age (56.5 ± 9.1 vs. 57.8 ± 9.7 years -P = 0.783); height (161.8 ± 7.4 vs. 166.8 ± 2.8 cm -P = 0.162); weight (79.5 ± 9.0 vs. 91.6 ± 22.8 kg -P = 0.096); and body mass index (30.7 ± 5.2, range = 22.8 to 39.5 vs. 32.7 ± 7.4, range = 23.4 to 44.3 kg/m 2 , -P = 0.51). Fifty-three percent of the patients in the study group were obese (BMI >30) against 80% in the control group. Eight of the fifteen patients in the study group and three of the five patients in the control group were smokers.
Comorbidities
Seven (47%) of the study group and two (40%) of the control group patients had COPD; three (20%) of the study group and one (20%) of the control group patients suffered from mild hypertension; and seven (47%) patients of the study group and two (40%) patients of the control group had diabetes mellitus. They were all under satisfactory clinical control with treatment for their respective ailments. Table 1 shows that the baseline Epworth sleepiness score (ESS), polysomnography data, and pre-and post-bronchodilator spirometry test values did not show any statistically significant difference in the two groups of patients.
It can be concluded, therefore, that the two groups of patients were indeed matched and comparable for their clinical profile, associated comorbidities, sleep, PSG, and spirometry test values -the small number of patients in the control group notwithstanding.
Evaluation of nasal continuous positive airway pressure therapy
The Epworth sleepiness score showed statistically significant improvement after four-weeks of nCPAP therapy in the study group; the same was unchanged after four weeks in the control group patients, who were not treated with nCPAP [ Table 1 ].
It can be seen from Table 2 that a four-week nasal CPAP therapy had produced a statistically significant relief of OSAHS symptoms in the study group, but not in the control group patients. Table 3 shows that the nCPAP therapy produced statistically significant improvement (35%) in the 6MWD, as well as dyspnea and fatigue in the study group patients. No such beneficial effects were seen after four weeks of 'just observation' in the control group.
Cardiopulmonary exercise test
All patients in the study and control groups successfully completed the symptom-limited incremental exercise test at the baseline as well as after four weeks, without any suggestive evidence of cardiac ischemia, exaggerated by hypertensive response or dysrrhythmia. The CPET data presented in Table 4 shows that a four-week treatment with nCPAP produced statistically significant improvement in the exercise capacity of the study group patients. The duration of exercise and power output -before the limiting symptoms appeared -increased by approximately 44 and 36%, respectively. The peak oxygen uptake increased by 36% (from 51 to 71% predicted). Furthermore, the anaerobic threshold value increased; the symptoms of dyspnea and fatigue were relieved; and at the peak of exercise, the SpO2 and oxygen pulse showed significant improvement. A small, but statistically significant decrease in diastolic blood pressure was observed at the peak of exercise. The findings were suggestive of a significant improvement in the cardiovascular function with better muscle blood flow, pulmonary gas exchange, and energy production. No such beneficial effects were discernible in the control group patients. 
Mechanisms underlying the limitation of exercise capacity
The limitation of exercise capacity in OSAHS can be adequately explained by: (i) Limitation of ventilation (VE MAX /MVV X 100 >85% or a respiratory frequency that is >60 per minute); (ii) cardiovascular impairment (heart rate reserve <15 beats per minute or an oxygen pulse <80%); and deconditioning of the musculoskeletal system (AT is low and there is a shift in the HR/VO 2 relationship to the left). Table 5 and Figure 1 depict the role of impaired ventilatory, cardiovascular, and musculoskeletal systems, underlying the limitation of exercise in the study group compared to the control group patients. The mechanisms in the study group patients were assessed to be ventilatory in three; cardiovascular in thirteen; and deconditioning of the musculoskeletal system in three patients. Following nCPAP therapy, the corresponding numbers of patients were: Six, six, and three, respectively. The findings strongly suggested that post nCPAP there was a significant improvement in the function of the ventilatory, cardiovascular, and musculoskeletal systems. The corresponding figures in the control group patients at baseline/four-week were: Ventilatory (0/0); cardiovascular (5/5); and deconditioning of the musculoskeletal system (4/3) -indicating no change in the pattern of mechanisms underlying limitation of exercise.
DISCUSSION
The present study was apparently limited by the following factors: (i) It was not a double-blind, placebo-controlled study and allotment to each arm was not randomized. This could not have been done for ethical considerations.
(ii) The sample size was inadequate, as the control group had only five patients compared to fifteen in the study group. There was a practical difficulty to enroll patients in the control group, as very few patients actually refused nCPAP therapy. (iii) Comorbidities such as COPD, hypertension, and diabetes were seen in significant numbers in both groups. It was difficult to get patients with pure OSAHS in a tertiary care hospital. A statistical analysis of the baseline data of patients in the two groups, however, provided convincing evidence that the two groups, for the purpose of the present study, were comparable, and the results of the nCPAP therapy were conclusive. For example, the control group patients were matched with the study group patients with no statistically significant difference in their physical characteristics, smoking habits, clinical profile, including comorbidities, baseline sleep, and PSG variables, and the indices of a 6MWT and CPET. Furthermore, the results of the nCPAP therapy in study group patients were statistically significantly superior to those of the control group patients.
Several factors may singly or in combination contribute to the limitation of exercise in OSAHS patients. These include: (i) Lack of physical fitness resulting from disturbed sleep, daytime somnolence, obesity, chronic tiredness, and body deconditioning on account of a reduced level of daily activity; (ii) obesity-related increased resistance to breathing and respiratory muscle dysfunction adding to dyspnea and daytime hypoxemia; (iii) there was also direct and indirect evidence to suggest that impaired cardiovascular function played a significant role in the impairment of exercise capacity. [9] [10] [11] 14] In a large Polish study of OSAHS (111 participants; age = 50.2 ± 10 years; BMI = 31.4 ± 4.6 kg/m 2 ; AHI = 47.2 ± 23.1/hour), the impairment of exercise tolerance was directly correlated to the severity of OSA and exaggerated hemodynamic response to exercise (BP >220 mmHg in 20% patients) and slow post-exercise blood pressure recovery of blood pressure. [27] In the present study (15 participants, age = 56.5 ± 9.1 years; BMI 30.1 ± 4.6 kg/m 2 ; AHI = 35.32 ± 16.99/hr), comparable hemodynamic responses to exercise, although smaller in magnitude, were observed. The quantitative difference in the responses may be explained by the fact that our patients had comparatively less severe OSAHS than that of the Polish study and they were also of a different ethnicity.
The results of the present study clearly demonstrated that even short-term use of the nCPAP therapy significantly relieved the disabling symptoms of OSAHS and improved the exercise capacity, when compared to the control group patients, who were not treated with it. The improvement of exercise capacity is possibly multifactorial in nature. Earlier studies reported that CPAP produced a significant reduction in the Epworth sleepiness score (ESS) in OSAHS patients after CPAP therapy, more so if the baseline ESS was >11.0, [28] The findings of this study are supportive of this observation, in that, ESS decreased from a baseline value of 12.93 ± 1.22 to 4.0 ± 1.55 after nCPAP therapy, while it remained high and unaffected in the control group patients. Compliance to CPAP is the single most important determinant of the clinical outcome, but can be problematic. 'What is good compliance' is highly debatable, but most workers agree that four or more hours of nCPAP per night is adequate to relieve the symptoms. [18] In our study, the CPAP machine had an in-built mechanism to record the time duration for which the machine was actually used. Relief of OSAHS symptoms would directly improve the general well-being and also elevate the mood of the patient, which helped in increasing exercise tolerance.
The improvement in exercise capacity may be attributed to a decrease in the production of ROS (reactive oxygen species), IL-8, TNF-alpha, and IL-6, and the consequent improvement in the function of the cardiovascular, ventilatory, and musculoskeletal systems. [7, 8, 29] A small, but statistically significant decrease in diastolic ABP at the peak of 6MWT in our patients strongly suggested a decrease in peripheral vascular resistance and improved muscle blood flow during exercise. However, this finding needs to be confirmed in a larger study sample.
Going by the analogy of COPD patients in whom >70 m improvement in 6MWD after intervention is considered significant, [30] a mean increase of 112 m in 6MWD after nCPAP in our study definitely indicates a marked improvement in the exercise capacity.
The sensations of fatigue and perceived dyspnea (Borg scale) both at baseline and at the peak of 6MWT were significantly relieved after nCPAP therapy. It may be noted that echocardiography showed evidence of a diastolic dysfunction in 60% of the cases. After the nCPAP therapy, a decrease in heart rate and diastolic blood pressure, with improved muscle blood flow as a result of improved cardiac function, suggest a cardiac etiology for fatigue and perceived dyspnea.
At baseline, 80% of the patients in the study group and 40% of the patients in the control group showed a significant decrease (>4%) in arterial oxygen saturation, along with a fall in the oxygen pulse value, post exercise. After the CPAP therapy, a significant improvement was seen in both these parameters. This could be attributed to an improvement in the cardiac output and possibly improved gas exchange in a proportion of patients who had COPD. [31] At baseline, the cardiovascular function was limited in 87% of the patients, as reflected by the decreased heart rate reserve and low oxygen pulse, while after CPAP therapy only 40% of the patients showed residual cardiovascular limitation.
Significant improvement in the anaerobic threshold meant an increase in the aerobic capacity, and hence, exercise duration and mean maximum load (work done/ power) sustained by the study group patients. Obstructive sleep apnea produced reduction of ventilatory and heart rate reserves. After CPAP therapy, there was a significant improvement in exercise ventilation, suggesting that the patients could achieve exercise VE close to the predicted maximal ventilation, with decreased dyspnea and fatigue.
It may be noted that most patients stopped exercise primarily due to leg fatigue or a subjective sensation of dyspnea, but with no ventilatory limitation such as significant ventilatory reserve was seen at the termination of the exercise. After CPAP therapy, many more patients could perform the test to the maximal ventilation capacity -secondary to improvement in the degree of fatigue after CPAP therapy. Prior to CPAP therapy 87% of the patients had deconditioning of the musculoskeletal system, as reflected by low AT and shift of the AT and HR/VO 2 relationship to the left, while after CPAP therapy only 20% of patients showed deconditioning of the musculoskeletal system. The findings are supported by a significant improvement in AT and normalization of the HR/VO 2 relationship. Additionally, there has been significant improvement in fatigue. These beneficial effects could either result from decreased peripheral vascular resistance and improved muscle blood flow or decreased sympathetic activity improving the glycogen synthetase activity, and thus, the intramyocytic glycogen store.
Another possible explanation of improvement in exercise capacity could be the nocturnal CPAP acting as a noninvasive ventilator support to patients with an overlap of COPD with OSAHS.
CONCLUSION
To conclude, short-term use of nCPAP therapy for four weeks in OSAHS executing the requisite compliance in our study has undoubtedly produced very encouraging results, although the long-term benefits still remain to be demonstrated. Overall, considerable improvement in the general well-being and exercise capacity of patients is likely to have a far-reaching impact, as improved daytime functioning with enhanced quality of life perceived by patients may not only be reflected in improved compliance in CPAP use, but may also lead to the long-term beneficial effects on the cardiometabolic profile of these patients. Hence, more rigorous, multicentered clinical trials should be planned to further elaborate on this aspect of OSAHS.
It may be of some interest to readers; to know that since the completion of this study; the definitions of apnea and hypopnea have been revised by the American Academy of Sleep Medicine. [32] "Apnea is scored when there is a drop in the peak signal excursion by more than or equal to 90% of the pre-event baseline using an oronasal thermal sensor for more than or equal to 10 seconds." "Hypopnea is scored when peak signal excursions drop by more than or equal to 10 seconds in association with either more than or equal to 3% arterial oxygen desaturation or an arousal". The criteria of defining apnea/hypopnea used in the present study are perhaps slightly more stringent. [21] [Downloaded free from http://www.lungindia.com on Thursday, June 25, 2015, IP: 208.52.133.66] 
